Ultragenyx Pharmaceutical (RARE) Total Non-Current Liabilities (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Total Non-Current Liabilities for 14 consecutive years, with $397.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 8.28% year-over-year to $397.0 million; the TTM figure through Mar 2026 stood at $397.0 million (up 8.28% YoY), while the FY2025 annual figure was $1.6 billion, up 270.78% from the prior year.
• Total Non-Current Liabilities slipped to $397.0 million in Q1 2026 per RARE's latest filing, from $1.6 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $1.6 billion in Q4 2025 and bottomed at $232.0 million in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $772.8 million across 5 years, with a median of $638.8 million in 2022.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 464.18% — and 2024, when it sank 72.43%.
• Ultragenyx Pharmaceutical's Total Non-Current Liabilities stood at $1.2 billion in 2022, then sank by 70.27% to $353.3 million in 2023, then rose by 19.17% to $421.0 million in 2024, then soared by 270.78% to $1.6 billion in 2025, then slumped by 74.57% to $397.0 million in 2026.
• Business Quant data shows RARE's Total Non-Current Liabilities at $397.0 million in Q1 2026, $1.6 billion in Q4 2025, and $1.2 billion in Q3 2025.